IthaChrom

Ret. time (minutes) From: To:
Area (%) From: To:
ID Hb Variant Gene Instrument Method Area (%) Ret Time (min) Comments
ID Hb Variant Gene Instrument Method Comments
3Hb I-Interlakenα1D-10Dual Kit Program24.51.45Heterozygous[PDF]
6HbSβD-10Dual Kit Program34.24.06Heterozygous / Sickle Cell Trait[PDF]
14HbCβD-10Dual Kit Program82.54.82Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.[PDF]
26HbEβD-10Dual Kit Program28.93.15Heterozygous[PDF]
27HbSβD-10Dual Kit Program52.74.04Compound heterozygote between HbS and HPFH [PDF]
45HbSβD-10Dual Kit Program21.34.11HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2). [PDF]
49Hb SiirtβD-10Dual Kit Program80.51.69Heterozygote clinically normal, the mild thalassemic syndrome observed may be in relation with the associated alpha gene abnormality (triple alpha). Hb Siirt elutes together with HbA. [PDF]
52Hb G-Honoluluα1 or α2D-10Dual Kit Program19.43.83Heterozygous. Clinically normal.[PDF]
55Hb St. Claudeα1 or α2D-10Dual Kit Program21.81.42Heterozygous. Clinically normal. [PDF]
58Hb G-CoushattaβD-10Dual Kit Program352.7Homozygous or associated with beta (0) thal.[PDF]
61Hb CamdenβD-10Dual Kit Program50.10.75Clinically normal. Elutes near, or at the position of Hb A1c.[PDF]
65Hb DhofarβD-10Dual Kit Program23.53.43Thalassemic Hb (in cis with a beta (+)-thalassemic mutation). [PDF]
70Hb Pierre-BéniteβD-10Dual Kit Program83.31.66This variant displays a high oxygen affinity and leads to erythrocytosis. Elutes as HbA0. [PDF]
73Hb BicêtreβD-10Dual Kit Program83.41.69Unstable variant. Elutes with HbA.[PDF]
77Hb M-SaskatoonβD-10Dual Kit Program6.94.7Methemoglobinemia and unstable variant. [PDF]
81Hb RainierβD-10Dual Kit Program73.21.69Increased oxygen affinity leading to erythrocytosis. Elutes as a shoulder in the descending part of HbA. [PDF]
85Hb J-BaltimoreβD-10Dual Kit Program42.91.52Clinically normal.[PDF]
89Hb AcharnesβD-10Dual Kit Program81.71.7 Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part.[PDF]
93Hb Chadα1 or α2D-10Dual Kit Program22.54.49Heterozygous. Clinically normal.[PDF]
97Hb Roanneα1 or α2D-10Dual Kit Program871.7Heterozygote clinically normal. Elutes as HbA.[PDF]
101Hb ProvidenceβD-10Dual Kit Program16.40.97This variant is spontaneously deaminated X-Asn 13-19%; X-Asp 32-33% leading to several fast eluting peaks. [PDF]
102Hb Toulonα2D-10Dual Kit Program33.52.96Heterozygote clinically normal. Elutes in the HbA2 window.[PDF]
105Hb D-Ouled RabahβD-10Dual Kit Program48.32.64Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC.[PDF]
109Hb Lyon-Bronα2D-10Dual Kit Program28.71.42Heterozygous. Slightly decreased oxygen affinity, mild anaemia.[PDF]
114Hb Saint-JacquesβD-10Dual Kit Program76.11.72Heterozygous. Hb variant with increased oxygen affinity.[PDF]
120Hb Gerlandα2D-10Dual Kit Program87.41.68Heterozygous. Elutes with HbA. Clinically asymptomatic neutral alpha chain variant. [PDF]
125Hb AubagneβD-10Dual Kit Program82.71.69Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0. [PDF]
129Hb Stanleyville-IIα2D-10Dual Kit Program31.24.01Heterozygous. Clinically normal.[PDF]
133Hb J-Sardegnaα2D-10Dual Kit Program300.51Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.[PDF]
137Hb Russα1D-10Dual Kit Program15.34.09Heterozygous. Elutes in HbS window. Clinically normal. [PDF]
141Hb K WoolwichβD-10Dual Kit Program33.50.65
145Hb MaputoβD-10Dual Kit Program553.05Clinically normal. Elutes as HbA2. [PDF]
149Hb Brem-sur-MerβD-10Dual Kit Program721.72Clinically and hematologically normal. Elutes as HbA.[PDF]
153Hb Fannin-Lubbock IIβD-10Dual Kit Program341.54This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal. [PDF]
157Hb Passyα2D-10Dual Kit Program74.71.68Heterozygous. Unstable variant.[PDF]
159Hb Handsworthα1D-10Dual Kit Program14.94.17Heterozygous. Clinically normal.[PDF]
161Hb Shimonosekiα1 or α2D-10Dual Kit Program14.74.17Heterozygous. Elutes as HbS. [PDF]
165Hb Lombardα2D-10Dual Kit Program0.52.55Heterozygous. Elutes as a shoulder in the descending part of the HbA peak. [PDF]
170Hb J-Tongarikiα1 or α2D-10Dual Kit Program20.31.59Heterozygous. Associated with alpha 3.7. [PDF]
174Hb D-IranβD-10Dual Kit Program452.64Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.[PDF]
178Hb YaoundeβD-10Dual Kit Program731.72Clinically normal. Elutes as HbA. [PDF]
182Hb Dunnα1 or α2D-10Dual Kit Program14.43.8Heterozygote. Elutes in Hb D window.[PDF]
186Hb J-Torontoα1 or α2D-10Dual Kit Program17.91.58Heterozygote. Clinically normal.[PDF]
190Hb Chicagoα2D-10Dual Kit Program82.31.69Heterozygous. Elutes as HbA. [PDF]
195Hb HikariβD-10Dual Kit Program73.71.72Clinically normal. Elutes in HbA window. [PDF]
199Hb G-SzuhuβD-10Dual Kit Program32.24.17Clinically normal. Elutes in HbS window. [PDF]
203Hb Ambroise Pareα2D-10Dual Kit Program79.71.67Heterozygous. Elutes with HbA. [PDF]
207Hb Groene Hartα1D-10Dual Kit Program79.61.68Mild non-deletional alpha thal variant. Migrates as HbA. [PDF]
211Hb Q-Thailandα1D-10Dual Kit Program22.54.18heterozygote[PDF]
216Hb Milledgevilleα1 or α2D-10Dual Kit Program5.81.44Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
220Hb Nunobikiα1 or α2D-10Dual Kit Program5.81.44Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
224Hb Summer HillβD-10Dual Kit Program35.83.88Heterozygote. Clinically normal. Elutes in HbS window.[PDF]
226Hb Fort de Franceα1 or α2D-10Dual Kit Program64.11.66Heterozygote. Elutes in the window of HbA2.[PDF]
228Hb J-Broussaisα1 or α2D-10Dual Kit Program141.12Heterozygote. Elutes near or with HbA1c. Clinically normal. [PDF]
230HbSβD-10Dual Kit Program83.34.02Homozygote. Classical chromatogram of an SS patient. [PDF]
232Hb Fort de Franceα1 or α2D-10Dual Kit Program16.13.06Compound heterozygote. In this case HbA0 is a result of transfusion.[PDF]
233Hb K-IbadanβD-10Dual Kit Program7.81.38Heterozygote. Clinically normal.[PDF]
236HbSβD-10Dual Kit Program88.54.04Homozygous Hb S. The trace amount of HbA remains from a blood transfusion.[PDF]
241HbSβD-10Dual Kit Program70.34.04Homozygous HbS recently transfused. [PDF]
247HbSβD-10Dual Kit Program23.34.1HbS carrier with homozygous alpha + thalassemia.[PDF]
251HbSβD-10Dual Kit Program74.14.07[PDF]
254Hb G-Philadelphiaα1 or α2D-10Dual Kit Program303.92Heterozygous. Associated with alpha thal. [PDF]
258HbCβD-10Dual Kit Program264.7Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis.[PDF]
262HbSβD-10Dual Kit Program74.84.04Classical chromatogram of a SS patient, the high HbF level suggests that the patient may be heterozygote (or perhaps homozygote) for one of the haplotype stimulating HbF synthesis.[PDF]
265HbCβD-10Dual Kit Program32.34.7heterozygote[PDF]
269Hb D-IranβD-10Dual Kit Program14.32.59heterozygote[PDF]
273Hb Hasharonα1D-10Dual Kit Program21.54.53heterozygote[PDF]
277Hb Hopkins-IIα1 or α2D-10Dual Kit Program18.31.41heterozygote[PDF]
281Hb J-BangkokβD-10Dual Kit Program39.81.68heterozygote[PDF]
285Hb J-Broussaisα1 or α2D-10Dual Kit Program31.10.96Heterozygote. Elutes with HbA1c.[PDF]
289Hb J-Paris-Iα1D-10Dual Kit Program25.51.5heterozygote[PDF]
293Hb J-Sardegnaα2D-10Dual Kit Program36.10.46Heterozygote. Elutes together with HbF.[PDF]
297Hb Le Lamentinα2D-10Dual Kit Program24.81.36heterozygote[PDF]
301Hb O-ArabβD-10Dual Kit Program29.44.57Heterozygote, clinically normal.[PDF]
305Hb O-Padovaα1 or α2D-10Dual Kit Program14.24.42Heterozygote, clinically normal. [PDF]
309Hb Q-Indiaα1D-10Dual Kit Program14.84.37Heterozygote. Clinically normal.[PDF]
313HbSβD-10Dual Kit Program32.44.08Homozygous HbS recently transfused (Exchange transfused) [PDF]
317Hb D-IbadanβD-10Dual Kit Program34.13.51Carrier. Clinically normal. [PDF]
321Hb VallettaβD-10Dual Kit Program84.11.69Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta. [PDF]
327Hb St. Luke'sα1D-10Dual Kit Program8.54.21Heterozygous. Elutes with HbS. [PDF]
331Hb Sunshine Sethα2D-10Dual Kit Program14.84.43heterozygote[PDF]
335HbEβD-10Dual Kit Program87.32.87Homozygote.[PDF]
339Hb TacomaβD-10Dual Kit Program67.51.7[PDF]
343Hb Old Dominion/Burton-upon-Trent (OD/BuT)βD-10Dual Kit Program36.31.52heterozygote[PDF]
347Hb Hopkins-IIα1 or α2D-10Dual Kit Program21.41.39Heterozygote.[PDF]
351Hb G-Philadelphiaα1 or α2D-10Dual Kit Program22.53.96Heterozygous. Associated with alpha thal.[PDF]
357Hb Goudaα2D-10Dual Kit Program28.71.43Heterozygote. Clinically normal.[PDF]
361HbCβD-10Dual Kit Program75.54.69HbC homozygous or compound heterozygous with beta zero thalassaemia. [PDF]
365Hb Le Lamentinα2D-10Dual Kit Program28.81.38heterozygote[PDF]
369Hb J-Meerutα2D-10Dual Kit Program9.11.42heterozygote[PDF]
373Hb Winnipegα1D-10Dual Kit Program16.74.46Heterozygote.[PDF]
376Hb Seal Rockα2D-10Dual Kit Program1.54.59Heterozygous. Modified C-terminal sequence.[PDF]
380Hb D-PunjabβD-10Dual Kit Program38.13.78heterozygote[PDF]
384Hb G-AccraβD-10Dual Kit Program40.63.53Normal in the heterozygote.[PDF]
388Hb HopeβD-10Dual Kit Program49.20.73In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote. [PDF]
392Hb AustinβD-10Dual Kit Program43.81.47Normal in the heterozygote.[PDF]
396HbSβD-10Dual Kit Program26.44.09HbS carrier with alpha thalassemia (homoz. alpha 3.7). [PDF]
400HbSβD-10Dual Kit Program304.09HbS carrier + alpha-thal 2 (-3.7 del.). [PDF]
405Hb G-CopenhagenβD-10Dual Kit Program44.62.91Clinically normal. Elutes together with HbA2. [PDF]
409Hb G-San JoséβD-10Dual Kit Program314.17Clinically normal. Elutes in S Window. [PDF]
413HbCβD-10Dual Kit Program79.34.69Homozygote.[PDF]
417Hb Santa ClaraβD-10Dual Kit Program45.31.43Heterozygote.[PDF]
421Hb D-PunjabβD-10Dual Kit Program293.81Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes. [PDF]
425Hb Hasharonα1D-10Dual Kit Program25.44.56Heterozygote with alpha 3.7. Clinically normal in heterozygote. [PDF]
429Hb Hasharonα1D-10Dual Kit Program29.14.56Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
433HbEβD-10Dual Kit Program29.62.96heterozygote[PDF]
438Hb AbruzzoβD-10Dual Kit Program46.12.72Hb with increased oxygen affinity. [PDF]
441Hb G-San JoséβD-10Dual Kit Program28.54.18Clinically normal. Elutes in S Window. [PDF]
445Hb RomaβD-10Dual Kit Program28.54.18Elutes with HbA. [PDF]
452Hb RandwickβD-10Dual Kit Program81.41.69Elutes with HbA. Mildly unstable. [PDF]
458HbEβD-10Dual Kit Program19.92.96HbE heterozygote with alpha-thal 1 heterozygote. [PDF]
462HbEβD-10Dual Kit Program28.82.92Association of HbE and Hb Constant Spring[PDF]
467HbSβD-10Dual Kit Program67.94.03Heterozygote for Hb S/beta zero thal (Beta(0) CD39 (C/T)) [PDF]
470Hb ShelbyβD-10Dual Kit Program11.73.06Compound heterozygous Hb Shelby / Beta zero Thalassemia. [PDF]
473Hb ShelbyβD-10Dual Kit Program5.83.1heterozygote[PDF]
477Hb D-PunjabβD-10Dual Kit Program70.83.7Double heterozygote Hb D-Punjab and beta-thalassaemia.[PDF]
482Hb VallettaβD-10Dual Kit Program66.31.74Compound heterozygote with Hb Lepore. Elutes as HbA0. [PDF]
486Hb D-PunjabβD-10Dual Kit Program813.74[PDF]
488HbCβD-10Dual Kit Program29.64.7compounnd heterozygote for HbC and Hb Korle Bu[PDF]
490HbSβD-10Dual Kit Program31.44.07Compound heterozygote for HbC and HbS[PDF]
493Hb RandwickβD-10Dual Kit Program52.41.82Double heterozygote for Hb Randwick and beta-thalassaemia. [PDF]
496HbSβD-10Dual Kit Program39.54.22Hb S/beta thal (probably a delta-beta thalassemia). [PDF]
499HbSβD-10Dual Kit Program84.12Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.[PDF]
10HbSβD-10HbA1c Program401.65Heterozygous / Sickle Cell Trait[PDF]
12HbSβD-10HbA1c Program81.21.65Homozygous[PDF]
18HbEβD-10HbA1c Program31.41.59Heterozygous[PDF]
20HbEβD-10HbA1c Program80.81.58Homozygous[PDF]
22Hb D-PunjabβD-10HbA1c Program41.51.63Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS. [PDF]
24Hb O-ArabβD-10HbA1c Program64.91.49Heterozygous; Heterozygote clinically normal. Homozygote present with a mild microcytic anemia. When associated to HbS leads to a severe sickle cell anemia.[PDF]
30Hb D-PunjabβD-10HbA1c Program41.51.63Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS. [PDF]
32HbCβD-10HbA1c Program46.51.77Heterozygote[PDF]
34HbCβD-10HbA1c Program891.76Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia. [PDF]
36HbSβD-10HbA1c Program38.21.77Compound heterozygote between HbS and HbC[PDF]
503HbSβD-10Dual Kit Program54.44.07HbS homozygous with HPFH. [PDF]
508HbSβD-10Dual Kit Program464.08Compound heterozygote for HbS and HbC, together with alpha-thal 2. [PDF]
509HbCβD-10Dual Kit Program46.44.7Compound heterozygote for HbS and HbC[PDF]
514HbSβD-10Dual Kit Program69.24.05Compound heterozygote for HbS and Beta (+) thal [PDF]
517HbSβD-10Dual Kit Program46.14.06Compound heterozygote for HbS and HbC[PDF]
518HbCβD-10Dual Kit Program46.34.7Compound heterozygote for HbS and HbC[PDF]
520HbCβD-10Dual Kit Program46.35.12Compound heterozygote for HbS and HbC[PDF]
523HbSβD-10Dual Kit Program58.94.06Compound heterozygote for HbS and B (+) thalassaemia.[PDF]
527HbSβD-10Dual Kit Program44.44.07Compound heterozygote for HbS and HbC[PDF]
528HbCβD-10Dual Kit Program43.64.71Compound heterozygote for HbS and HbC[PDF]
535Hb D-PunjabβD-10Dual Kit Program37.93.74Compound heterozygote for HbS and Hb D-Punjab[PDF]
542HbCβD-10Dual Kit Program50.44.7Compound heterozygote for HbC and (delta-beta) zero thalassaemia. [PDF]
546HbCβD-10Dual Kit Program59.44.7heterozygote[PDF]
552Hb A2' or Hb B2δD-10Dual Kit Program1.54.19[PDF]
556Hb N-BaltimoreβD-10Dual Kit Program80.81.46Hb N-Baltimore / Beta zero thalassaemia. Clinical normal. [PDF]
559HbSβD-10Dual Kit Program30.74.08HbS carrier with alpha-thalassaemia (α3.7/αα). [PDF]
563Hb CamperdownβD-10Dual Kit Program46.70.68Mildly unstable. [PDF]
564HbEβD-10Dual Kit Program41.22.78Association of HbE and beta-thalassaemia. [PDF]
568HbCβD-10Dual Kit Program48.14.79Compound heterozygote for HbC and Hb O-Arab.[PDF]
569Hb O-ArabβD-10Dual Kit Program41.64.56Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome. [PDF]
576Hb Mexicoα1 or α2D-10Dual Kit Program27.31.37Heterozygous.[PDF]
581HbIα1D-10Dual Kit Program10.41.36heterozygote[PDF]
585Hb Lepore-Boston-WashingtonδD-10Dual Kit Program4.82.69Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.[PDF]
585Hb Lepore-Boston-WashingtonβD-10Dual Kit Program4.82.69Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC.[PDF]
589Hb M-Milwaukee-2βD-10Dual Kit Program31.64.71Congenital methemoglobinemia.[PDF]
593Hb Lepore-Boston-WashingtonδD-10Dual Kit Program5.32.69Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
593Hb Lepore-Boston-WashingtonβD-10Dual Kit Program5.32.69Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
599Hb Aichiα1 or α2D-10Dual Kit Program21.94.05Heterozygous. Elutes as HbS. [PDF]
603Hb Setifα2D-10Dual Kit Program3.51.43Heterozygote. Elutes with HbA. [PDF]
606Hb ProvidenceβD-10Dual Kit Program31.30.3This variant is spontaneously deaminated X-Asn 13-19%; X-Asp 32-33% leading to several fast eluting peaks. [PDF]
607Hb ProvidenceβD-10Dual Kit Program16.40.97This variant is spontaneously deaminated X-Asn 13-19%; X-Asp 32-33% leading to several fast eluting peaks. [PDF]
608Hb Setifα2D-10Dual Kit Program11.34.4Heterozygote. [PDF]
2Hb I-Interlakenα1VARIANTβ-thal Short Program24.91.62Heterozygous[PDF]
7HbSβVARIANTβ-thal Short Program34.54.26Heterozygous / Sickle Cell Trait[PDF]
15HbCβVARIANTβ-thal Short Program84.25.09Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.[PDF]
43HbSβVARIANTβ-thal Short Program77.24.3Compoud heterozygote between HbS and beta (0) thal.[PDF]
46HbSβVARIANTβ-thal Short Program22.94.35HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2). [PDF]
50Hb SiirtβVARIANTβ-thal Short Program82.32.5Heterozygote clinically normal, the mild thalassemic syndrome observed may be in relation with the associated alpha gene abnormality (triple alpha). Hb Siirt elutes together with HbA.[PDF]
67Hb DhofarβVARIANTβ-thal Short Program13.93.84Thalassemic Hb (in cis with a beta (+)-thalassemic mutation). [PDF]
71Hb Pierre-BéniteβVARIANTβ-thal Short Program84.82.33This variant displays a high oxygen affinity and leads to erythrocytosis. Elutes as HbA0. [PDF]
74Hb BicêtreβVARIANTβ-thal Short Program80.62.34Unstable variant. Elutes with HbA.[PDF]
78Hb M-SaskatoonβVARIANTβ-thal Short Program9.34.91Methemoglobinemia and unstable variant.[PDF]
86Hb J-BaltimoreβVARIANTβ-thal Short Program40.81.8Clinically normal.[PDF]
90Hb AcharnesβVARIANTβ-thal Short Program30.22.28Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part.[PDF]
94Hb Chadα1 or α2VARIANTβ-thal Short Program25.24.89Heterozygous. Clinically normal.[PDF]
98Hb Roanneα1 or α2VARIANTβ-thal Short Program88.52.48Heterozygote clinically normal. Elutes as HbA.[PDF]
103Hb Toulonα2VARIANTβ-thal Short Program23.93.52Heterozygote clinically normal. Elutes in the HbA2 window.[PDF]
106Hb D-Ouled RabahβVARIANTβ-thal Short Program76.73.58[PDF]
110Hb Lyon-Bronα2VARIANTβ-thal Short Program30.71.73Heterozygous. Slightly decreased oxygen affinity, mild anaemia. [PDF]
115Hb Saint-JacquesβVARIANTβ-thal Short Program79.22.5Heterozygous. Hb variant with increased oxygen affinity.[PDF]
121Hb Gerlandα2VARIANTβ-thal Short Program85.72.46Heterozygous. Elutes with HbA. Clinically asymptomatic neutral alpha chain variant.[PDF]
124Hb Henri MondorβVARIANTβ-thal Short Program35.72.92Mild microcytic anaemia.[PDF]
126Hb AubagneβVARIANTβ-thal Short Program85.22.47Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.[PDF]
130Hb Stanleyville-IIα2VARIANTβ-thal Short Program29.94.18Heterozygous. Clinically normal. Elutes as HbS. [PDF]
134Hb J-Sardegnaα2VARIANTβ-thal Short Program29.31.28Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated. [PDF]
138Hb Russα1VARIANTβ-thal Short Program15.74.18Heterozygous. Elutes in HbS window. Clinically normal.[PDF]
142Hb K WoolwichβVARIANTβ-thal Short Program35.21.29Clinically and hematologically normal.[PDF]
146Hb MaputoβVARIANTβ-thal Short Program40.93.72Clinically normal. Elutes as HbA2.[PDF]
150Hb Brem-sur-MerβVARIANTβ-thal Short Program72.12.4Clinically and hematologically normal. Elutes as HbA. [PDF]
154Hb Fannin-Lubbock IIβVARIANTβ-thal Short Program36.51.82This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal. [PDF]
158Hb Passyα2VARIANTβ-thal Short Program78.12.44Heterozygous. Elutes with HbA. Unstable variant. [PDF]
160Hb Handsworthα1VARIANTβ-thal Short Program0.74.7Heterozygous. Clinically normal.[PDF]
162Hb Shimonosekiα1 or α2VARIANTβ-thal Short Program14.54.21Heterozygous. Elutes as HbS. [PDF]
166Hb Lombardα2VARIANTβ-thal Short Program872.45Heterozygous. Elutes with HbA.[PDF]
171Hb J-Tongarikiα1 or α2VARIANTβ-thal Short Program21.81.82Heterozygous. Associated with alpha 3.7 [PDF]
175Hb D-IranβVARIANTβ-thal Short Program40.33.55Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.[PDF]
179Hb YaoundeβVARIANTβ-thal Short Program76.52.46Clinically normal. Elutes as HbA. [PDF]
183Hb Dunnα1 or α2VARIANTβ-thal Short Program13.23.95Heterozygote. Elutes in HbD window.[PDF]
187Hb J-Tongarikiα1 or α2VARIANTβ-thal Short Program19.31.78Heterozygous. Associated with alpha 3.7 [PDF]
191Hb Chicagoα2VARIANTβ-thal Short Program842.47Heterozygous. Elutes as HbA. [PDF]
196Hb HikariβVARIANTβ-thal Short Program35.32.04Clinically normal. [PDF]
200Hb G-SzuhuβVARIANTβ-thal Short Program37.74.54Clinically normal. [PDF]
204Hb Ambroise Pareα2VARIANTβ-thal Short Program81.52.44Heterozygous. Elutes with HbA. [PDF]
208Hb Groene Hartα1VARIANTβ-thal Short Program81.92.46Mild non-deletional alpha thal variant. Migrates as HbA. [PDF]
212Hb Q-Thailandα1VARIANTβ-thal Short Program22.94.51heterozygote[PDF]
215Hb D-PunjabβVARIANTβ-thal Short Program80.74.05Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS. [PDF]
217Hb Milledgevilleα1 or α2VARIANTβ-thal Short Program18.42.19Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
221Hb Nunobikiα1 or α2VARIANTβ-thal Short Program12.81.51Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
225Hb Summer HillβVARIANTβ-thal Short Program38.44.24Heterozygote. Clinically normal. Elutes in HbS window.[PDF]
227Hb Fort de Franceα1 or α2VARIANTβ-thal Short Program16.33.52Heterozygote. Elutes in the window of HbA2.[PDF]
229Hb J-Broussaisα1 or α2VARIANTβ-thal Short Program24.81.62Heterozygote. Elutes near or with HbA1c. Clinically normal. [PDF]
231HbSβVARIANTβ-thal Short Program38.44.24Homozygote. Classical chromatogram of an SS patient.[PDF]
234Hb K-IbadanβVARIANTβ-thal Short Program321.99Heterozygote. Clinically normal.[PDF]
238HbSβVARIANTβ-thal Short Program90.44.26Sickle cell disease. The trace amount of HbA remains from a blood transfusion.[PDF]
242HbSβVARIANTβ-thal Short Program74.54.26Homozygous HbS recently transfused. [PDF]
248HbSβVARIANTβ-thal Short Program22.44.25HbS carrier with homozygous alpha + thalassemia.[PDF]
255Hb G-Philadelphiaα1 or α2VARIANTβ-thal Short Program26.74.01Heterozygous. Eluates as HbD. Associated with alpha thal. [PDF]
259HbCβVARIANTβ-thal Short Program23.85.03Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. [PDF]
263HbSβVARIANTβ-thal Short Program80.84.38Classical chromatogram of a SS patient, the high HbF level suggests that the patient may be heterozygote (or perhaps homozygote) for one of the haplotype stimulating HbF synthesis.[PDF]
266HbCβVARIANTβ-thal Short Program37.64heterozygote[PDF]
270Hb D-IranβVARIANTβ-thal Short Program383.56Heterozygous. Elutes as HbA2 in CE-HPLC.[PDF]
274Hb Hasharonα1VARIANTβ-thal Short Program19.54.74heterozygote[PDF]
278Hb Hopkins-IIα1 or α2VARIANTβ-thal Short Program19.31.5heterozygote[PDF]
282Hb J-BangkokβVARIANTβ-thal Short Program38.71.9heterozygote[PDF]
286Hb J-Broussaisα1 or α2VARIANTβ-thal Short Program27.81.62Heterozygote. Elutes near or with HbA1c.[PDF]
290Hb J-Paris-Iα1VARIANTβ-thal Short Program26.31.7heterozygote[PDF]
294Hb J-Sardegnaα2VARIANTβ-thal Short Program34.81.18Heterozygote. Elutes together with HbF. [PDF]
298Hb Le Lamentinα2VARIANTβ-thal Short Program25.41.51heterozygote[PDF]
302Hb O-ArabβVARIANTβ-thal Short Program32.94.3Heterozygote, clinically normal. [PDF]
306Hb O-Padovaα1 or α2VARIANTβ-thal Short Program15.34.73Heterozygote. Clinically normal. [PDF]
310Hb Q-Indiaα1VARIANTβ-thal Short Program17.34.7Heterozygote. Clinically normal.[PDF]
314HbSβVARIANTβ-thal Short Program36.44.31HbS homozygote, transfused. [PDF]
318Hb D-IbadanβVARIANTβ-thal Short Program39.13.85Carrier. Clinically normal. [PDF]
322Hb VallettaβVARIANTβ-thal Short Program872.46Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.[PDF]
332Hb Sunshine Sethα2VARIANTβ-thal Short Program18.84.71heterozygote[PDF]
336HbEβVARIANTβ-thal Short Program76.43.65Homozygote.[PDF]
340Hb TacomaβVARIANTβ-thal Short Program72.12.41Heterozygote carriers are clinically normal.[PDF]
344Hb Old Dominion/Burton-upon-Trent (OD/BuT)βVARIANTβ-thal Short Program32.61.85heterozygote[PDF]
348Hb Hopkins-IIα1 or α2VARIANTβ-thal Short Program12.51.46Heterozygote.[PDF]
352Hb G-Philadelphiaα1 or α2VARIANTβ-thal Short Program21.74.04Heterozygous. Associated with alpha thal. [PDF]
358Hb Goudaα2VARIANTβ-thal Short Program30.91.64Heterozygote. Clinically normal.[PDF]
362HbCβVARIANTβ-thal Short Program79.45.06HbC homozygous or compound heterozygous with beta zero thalassaemia. [PDF]
366Hb Le Lamentinα2VARIANTβ-thal Short Program331.49heterozygote[PDF]
370Hb J-Meerutα2VARIANTβ-thal Short Program17.61.86heterozygote[PDF]
374Hb Winnipegα1VARIANTβ-thal Short Program184.74Heterozygote.[PDF]
377Hb Seal Rockα2VARIANTβ-thal Short Program1.94.7Heterozygous. Modified C-terminal sequence.[PDF]
381Hb D-PunjabβVARIANTβ-thal Short Program37.44.08heterozygote[PDF]
385Hb G-AccraβVARIANTβ-thal Short Program43.93.88Normal in the heterozygote. [PDF]
389Hb HopeβVARIANTβ-thal Short Program47.31.36In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote. [PDF]
393Hb AustinβVARIANTβ-thal Short Program45.61.64Normal in the heterozygote. [PDF]
397HbSβVARIANTβ-thal Short Program28.24.3HbS carrier with alpha thalassemia (homoz. alpha 3.7). [PDF]
401HbSβVARIANTβ-thal Short Program324.33HbS carrier + alpha-thal 2 (-3.7 del.). [PDF]
404Hb N-BaltimoreβVARIANTβ-thal Short Program83.71.65[PDF]
406Hb G-CopenhagenβVARIANTβ-thal Short Program40.63.74Clinically normal. Elutes together with HbA2. [PDF]
410Hb G-San JoséβVARIANTβ-thal Short Program34.54.54Clinically normal. [PDF]
414HbCβVARIANTβ-thal Short Program82.35.06Homozygote.[PDF]
418Hb Santa ClaraβVARIANTβ-thal Short Program46.71.65Heterozygote.[PDF]
422Hb D-PunjabβVARIANTβ-thal Short Program283.99Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.[PDF]
426Hb Hasharonα1VARIANTβ-thal Short Program25.74.74Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
430Hb Hasharonα1VARIANTβ-thal Short Program27.94.74Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
434HbEβVARIANTβ-thal Short Program253.63heterozygote[PDF]
442Hb G-San JoséβVARIANTβ-thal Short Program31.34.52Clinically normal. [PDF]
446Hb RomaβVARIANTβ-thal Short Program31.34.52Elutes with HbA. [PDF]
5Hb I-Interlakenα1VARIANT IIDual Kit Program24.31.56Heterozygous
9HbSβVARIANT IIDual Kit Program33.73.47Heterozygous / Sickle Cell Trait[PDF]
17HbCβVARIANT IIDual Kit Program82.34.42Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.[PDF]
38HbEβVARIANT IIDual Kit Program27.63.65Heterozygous[PDF]
39HbEβVARIANT IIDual Kit Program22.42.969Heterozygous[PDF]
44Hb ShelbyβVARIANT IIDual Kit Program73.64.74Compound heterozygote between Hb Shelby and beta (0) Thal.[PDF]
47HbSβVARIANT IIDual Kit Program23.84.46HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2).[PDF]
48HbSβVARIANT IIDual Kit Program21.33.49HbS heterozygote with alpha thalassaemia (HbS + alpha-thal 2).[PDF]
51Hb SiirtβVARIANT IIDual Kit Program80.31.76Heterozygote clinically normal, the mild thalassemic syndrome observed may be in relation with the associated alpha gene abnormality (triple alpha). Hb Siirt elutes together with HbA. [PDF]
53Hb G-Honoluluα1 or α2VARIANT IIDual Kit Program21.13.8Heterozygous. Clinically normal. Hb G-Honolulu elutes together with HbA2. [PDF]
54Hb G-Honoluluα1 or α2VARIANT IIDual Kit Program20.23.18
57Hb St. Claudeα1 or α2VARIANT IIDual Kit Program22.11.49Heterozygous. Clinically normal. [PDF]
60Hb G-CoushattaβVARIANT IIDual Kit Program61.12.69Homozygous or associated with beta (0) thal.
63Hb CamdenβVARIANT IIDual Kit Program50.30.87Clinically normal. Elutes near, or at the position of Hb A1c.[PDF]
69Hb DhofarβVARIANT IIDual Kit Program18.93.12Thalassemic Hb (in cis with a beta (+)-thalassemic mutation).[PDF]
72Hb Pierre-BéniteβVARIANT IIDual Kit Program83.21.753This variant displays a high oxygen affinity and leads to erythrocytosis. Elutes as HbA0. [PDF]
76Hb BicêtreβVARIANT IIDual Kit Program83.81.8Unstable variant. Elutes with HbA.[PDF]
80Hb M-SaskatoonβVARIANT IIDual Kit Program4.44.51Methemoglobinemia and unstable variant.[PDF]
84Hb RainierβVARIANT IIDual Kit Program72.21.77Increased oxygen affinity leading to erythrocytosis. Elutes as HbA.[PDF]
88Hb J-BaltimoreβVARIANT IIDual Kit Program43.91.567Clinically normal.[PDF]
92Hb AcharnesβVARIANT IIDual Kit Program80.11.776Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part. [PDF]
96Hb Chadα1 or α2VARIANT IIDual Kit Program20.64.115Heterozygous. Clinically normal.[PDF]
100Hb Roanneα1 or α2VARIANT IIDual Kit Program87.91.76Heterozygote clinically normal. Elutes as HbA.[PDF]
108Hb D-Ouled RabahβVARIANT IIDual Kit Program59.22.736[PDF]
113Hb Lyon-Bronα2VARIANT IIDual Kit Program29.91.502Heterozygous. Slightly decreased oxygen affinity, mild anaemia.[PDF]
117Hb Saint-JacquesβVARIANT IIDual Kit Program29.62.316Heterozygous. Hb variant with increased oxygen affinity.[PDF]
119Hb HamiltonβVARIANT IIDual Kit Program861.789Neutral variant, clinically normal. Elutes together with HbA on CE-HPLC. Abnormal chain could be observed by RP-HPLC. Diagnosis requires DNA studies.[PDF]
123Hb Gerlandα2VARIANT IIDual Kit Program8.12.609Heterozygous. Elutes with HbA. Clinically asymptomatic neutral alpha chain variant.[PDF]
128Hb AubagneβVARIANT IIDual Kit Program85.61.801Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.[PDF]
132Hb Stanleyville-IIα2VARIANT IIDual Kit Program32.13.401Heterozygous. Clinically normal. Elutes as HbS.[PDF]
136Hb J-Sardegnaα2VARIANT IIDual Kit Program25.40.676Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.[PDF]
140Hb Russα1VARIANT IIDual Kit Program163.483Heterozygous. Elutes in HbS window. Clinically normal.[PDF]
144Hb K WoolwichβVARIANT IIDual Kit Program37.20.859Clinically and hematologically normal.[PDF]
148Hb MaputoβVARIANT IIDual Kit Program40.12.98Clinically normal. Elutes as HbA2.[PDF]
152Hb Brem-sur-MerβVARIANT IIDual Kit Program1.53.027Clinically and hematologically normal. Elutes as HbA. [PDF]
156Hb Fannin-Lubbock IIβVARIANT IIDual Kit Program36.51.66This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal.[PDF]
164Hb MalmöβVARIANT IIDual Kit Program46.21.427High oxygen affinity variant, leads to erythrocytosis. Elutes together with HbA or before according to the chromatographic system used. [PDF]
169Hb Lombardα2VARIANT IIDual Kit Program87.91.809Heterozygous. Elutes as a shoulder in the descending part of the HbA peak. [PDF]
173Hb J-Tongarikiα1 or α2VARIANT IIDual Kit Program21.61.684Heterozygous. Associated with alpha 3.7 [PDF]
177Hb D-IranβVARIANT IIDual Kit Program40.32.823Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.[PDF]
181Hb YaoundeβVARIANT IIDual Kit Program73.21.822Clinically normal. Elutes as HbA. [PDF]
449Hb CamperdownβVARIANTβ-thal Short Program45.91.29Hb variant is mildly unstable. [PDF]
453Hb RandwickβVARIANTβ-thal Short Program82.62.38Elutes with HbA. Mildly unstable. [PDF]
459HbEβVARIANTβ-thal Short Program17.73.64HbE heterozygote with alpha-thal 1 heterozygote. [PDF]
463HbEβVARIANTβ-thal Short Program25.33.68Association of HbE and Hb Constant Spring[PDF]
471Hb ShelbyβVARIANTβ-thal Short Program10.63.61Compound heterozygous Hb Shelby / Beta zero Thalassemia. [PDF]
474Hb ShelbyβVARIANTβ-thal Short Program3.93.62heterozygote[PDF]
478Hb D-PunjabβVARIANTβ-thal Short Program73.74.01Double heterozygote Hb D-Punjab and beta-thalassaemia. [PDF]
483Hb VallettaβVARIANTβ-thal Short Program66.42.58Compound heterozygote with Hb Lepore. Elutes as HbA0. [PDF]
489HbCβVARIANTβ-thal Short Program325.1compound heterozygote for HbC and Hb Korle Bu[PDF]
491HbSβVARIANTβ-thal Short Program31.44.37compound heterozygote for HbC and HbS[PDF]
492HbCβVARIANTβ-thal Short Program29.95.11Compound heterozygote for HbC and HbS. Recently transfused.[PDF]
494Hb RandwickβVARIANTβ-thal Short Program67.72.64Double heterozygote for Hb Randwick and beta-thalassaemia. [PDF]
500HbSβVARIANTβ-thal Short Program124.22Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.[PDF]
504HbSβVARIANTβ-thal Short Program62.84.26HbS homozygous with HPFH.[PDF]
507HbSβVARIANTβ-thal Short Program79.74.37Homozygous HbS. HbA remains from a blood transfusion. [PDF]
510HbSβVARIANTβ-thal Short Program45.14.35Compound heterozygote for HbS and HbC[PDF]
511HbCβVARIANTβ-thal Short Program45.85.1Compound heterozygote for HbC and HbS[PDF]
515HbSβVARIANTβ-thal Short Program74.64.38Compound heterozygote for HbS and Beta (+) thal[PDF]
519HbSβVARIANTβ-thal Short Program45.84.37Compound heterozygote for HbS and HbC[PDF]
524HbSβVARIANTβ-thal Short Program64.24.32Compound heterozygote for HbS and B (+) thalassemia[PDF]
529HbSβVARIANTβ-thal Short Program44.74.36Compound heterozygote for HbS and HbC[PDF]
530HbCβVARIANTβ-thal Short Program45.95.11Compound heterozygote for HbS and HbC[PDF]
536Hb D-PunjabβVARIANTβ-thal Short Program40.74Compound heterozygote for HbS and Hb D-Punjab.[PDF]
537HbSβVARIANTβ-thal Short Program40.24.3Compound heterozygote for HbS and Hb D-Punjab[PDF]
543HbCβVARIANTβ-thal Short Program61.15.1Compound heterozygote for HbC and (delta-beta) zero thalassaemia. [PDF]
547HbCβVARIANTβ-thal Short Program625.1Compound heterozygote for HbC and beta-thalassaemia. [PDF]
553Hb A2' or Hb B2δVARIANTβ-thal Short Program1.54.47[PDF]
560HbSβVARIANTβ-thal Short Program31.64.35HbS carrier + alpha-thal 2 (-3.7 deletion). [PDF]
565HbEβVARIANTβ-thal Short Program473.73Association of HbE and beta-thalassaemia. [PDF]
570HbCβVARIANTβ-thal Short Program47.75.12Compound heterozygote for HbC and Hb O-Arab.[PDF]
571Hb O-ArabβVARIANTβ-thal Short Program44.84.85Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome. [PDF]
577Hb Mexicoα1 or α2VARIANTβ-thal Short Program27.81.75Heterozygous.[PDF]
582HbIα1VARIANTβ-thal Short Program14.81.39heterozygote[PDF]
586Hb Lepore-Boston-WashingtonδVARIANTβ-thal Short Program10.53.5Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
586Hb Lepore-Boston-WashingtonβVARIANTβ-thal Short Program10.53.5Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
590Hb M-Milwaukee-2βVARIANTβ-thal Short Program34.95.08Congenital methemoglobinemia.[PDF]
594Hb Lepore-Boston-WashingtonδVARIANTβ-thal Short Program9.73.42Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
594Hb Lepore-Boston-WashingtonβVARIANTβ-thal Short Program9.73.42Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
600Hb Aichiα1 or α2VARIANTβ-thal Short Program19.74.17Heterozygous. Elutes as HbS. [PDF]
604Hb Setifα2VARIANTβ-thal Short Program3.51.6Heterozygote. Elutes with HbA. [PDF]
609Hb Setifα2VARIANTβ-thal Short Program14.54.66Heterozygote. [PDF]
4Hb I-Interlakenα1VARIANT IIβ-thal Short Program24.81.63Heterozygous[PDF]
8HbSβVARIANT IIβ-thal Short Program34.64.4Heterozygous / Sickle Cell Trait[PDF]
16HbCβVARIANT IIβ-thal Short Program86.85.16Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal.[PDF]
28HbSβVARIANT IIβ-thal Short Program69.44.41Compound heterozygote for HbS and HPFH[PDF]
37HbEβVARIANT IIβ-thal Short Program25.13.66Heterozygous[PDF]
56Hb St. Claudeα1 or α2VARIANT IIβ-thal Short Program22.41.88Heterozygous. Clinically normal. [PDF]
59Hb G-CoushattaβVARIANT IIβ-thal Short Program75.13.48Homozygous or associated with beta (0) thal.[PDF]
62Hb CamdenβVARIANT IIβ-thal Short Program44.51.36Clinically normal. Elutes near, or at the position of Hb A1c.[PDF]
68Hb DhofarβVARIANT IIβ-thal Short Program12.83.92Thalassemic Hb (in cis with a beta (+)-thalassemic mutation). [PDF]
75Hb BicêtreβVARIANT IIβ-thal Short Program85.22.5Unstable variant. Elutes with HbA.[PDF]
79Hb M-SaskatoonβVARIANT IIβ-thal Short Program11.75Methemoglobinemia and unstable variant.[PDF]
82Hb RainierβVARIANT IIβ-thal Short Program78.12.48Increased oxygen affinity leading to erythrocytosis. Elutes as HbA.[PDF]
83Hb RainierβVARIANT IIβ-thal Short Program78.32.51Increased oxygen affinity leading to erythrocytosis. Elutes as a shoulder in the descending part of HbA[PDF]
87Hb J-BaltimoreβVARIANT IIβ-thal Short Program44.81.83Clinically normal.[PDF]
91Hb AcharnesβVARIANT IIβ-thal Short Program82.82.47Unstable variant. Chronic hemolytic anemia. Elutes together with HbA0 or as a shoulder in the ascending part. [PDF]
95Hb Chadα1 or α2VARIANT IIβ-thal Short Program23.64.96Heterozygous. Clinically normal. [PDF]
99Hb Roanneα1 or α2VARIANT IIβ-thal Short Program89.12.43Heterozygote clinically normal. Elutes as HbA.[PDF]
104Hb Toulonα2VARIANT IIβ-thal Short Program253.57Heterozygote clinically normal. Elutes in the HbA2 window.[PDF]
107Hb D-Ouled RabahβVARIANT IIβ-thal Short Program75.13.57[PDF]
111Hb Lyon-Bronα2VARIANT IIβ-thal Short Program30.11.82Heterozygous. Slightly decreased oxygen affinity, mild anaemia.[PDF]
116Hb Saint-JacquesβVARIANT IIβ-thal Short Program80.52.56Heterozygous. Hb variant with increased oxygen affinity.[PDF]
118Hb HamiltonβVARIANT IIβ-thal Short Program87.42.55Neutral variant, clinically normal. Elutes together with HbA on CE-HPLC. Abnormal chain could be observed by RP-HPLC. Diagnosis requires DNA studies.[PDF]
122Hb Gerlandα2VARIANT IIβ-thal Short Program87.62.47
127Hb AubagneβVARIANT IIβ-thal Short Program86.22.55Heterozygous. Unstable variant, mild hemolytic anaemia. Appears as a shoulder in the descending part of HbA0.[PDF]
131Hb Stanleyville-IIα2VARIANT IIβ-thal Short Program29.74.31Heterozygous. Clinically normal. Elutes as HbS.[PDF]
135Hb J-Sardegnaα2VARIANT IIβ-thal Short Program30.31.24Heterozygous. Elutes with HbF. DNA sequencing showed that the mutation leads to an Asn which is totally deamidated.[PDF]
139Hb Russα1VARIANT IIβ-thal Short Program15.14.32Heterozygous. Elutes in HbS window. Clinically normal.[PDF]
143Hb K WoolwichβVARIANT IIβ-thal Short Program34.41.29Clinically and hematologically normal.[PDF]
147Hb MaputoβVARIANT IIβ-thal Short Program39.63.74Clinically normal. Elutes as HbA2. [PDF]
151Hb Brem-sur-MerβVARIANT IIβ-thal Short Program76.52.58Clinically and hematologically normal. Elutes as HbA. [PDF]
155Hb Fannin-Lubbock IIβVARIANT IIβ-thal Short Program36.11.91This variant carries in addition to the mutation of Hb Fannin Lubbock [Gly>Asp] a second neutral mutation [beta Val>Leu] which modifies the retention time in RP-HPLC. Clinically normal.[PDF]
163Hb MalmöβVARIANT IIβ-thal Short Program18.31.7High oxygen affinity variant, leads to erythrocytosis. Elutes together with HbA or before according to the chromatographic system used. [PDF]
167Hb Lombardα2VARIANT IIβ-thal Short Program88.82.55Heterozygous. Elutes as a shoulder in the descending part of the HbA peak. [PDF]
172Hb J-Tongarikiα1 or α2VARIANT IIβ-thal Short Program22.61.91Heterozygous. Associated with alpha 3.7 [PDF]
176Hb D-IranβVARIANT IIβ-thal Short Program40.43.56Carrier. Clinically normal. Elutes as HbA2 in CE-HPLC. Compound heterozygotes HbS/Hb D-Iran behave clinically as HbA/HbS.[PDF]
180Hb YaoundeβVARIANT IIβ-thal Short Program75.22.55Clinically normal. Elutes as HbA. [PDF]
40HbCβVARIANT IIDual Kit Program - HbA1c41.72.04heterozygote[PDF]
41Hb D-PunjabβVARIANT IIDual Kit Program - HbA1c42.21.83Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS. [PDF]
42HbSβVARIANT IIDual Kit Program - HbA1c44.71.88Heterozygous / Sickle Cell Trait[PDF]
64HbEβVARIANT IIDual Kit Program - HbA1c85.91.737homozygote[PDF]
11HbSβVARIANT IIHbA1c Program39.21.94Sickle Cell Trait[PDF]
13HbSβVARIANT IIHbA1c Program84.41.93Homozygous[PDF]
19HbEβVARIANT IIHbA1c Program30.31.86Heterozygous[PDF]
21HbEβVARIANT IIHbA1c Program80.11.84Homozygous[PDF]
23Hb D-PunjabβVARIANT IIHbA1c Program401.9 Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS. [PDF]
25Hb O-ArabβVARIANT IIHbA1c Program31.32.02Heterozygous; Heterozygote clinically normal. Homozygote present with a mild microcytic anemia. When associated to HbS leads to a severe sickle cell anemia.[PDF]
29HbSβVARIANT IIHbA1c Program39.21.94Heterozygote / Sickle Cell Trait[PDF]
31Hb D-PunjabβVARIANT IIHbA1c Program401.9Heterozygote; Heterozygous; Clinically normal in heterozygotes. Mild anemia in homozygotes. Causes a severe sickle cell disease when associated to HbS. [PDF]
33HbCβVARIANT IIHbA1c Program37.12.11Heterozygote[PDF]
35HbCβVARIANT IIHbA1c Program972.1Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia.[PDF]
185Hb Dunnα1 or α2VARIANT IIDual Kit Program13.43.257Heterozygote. Elutes in HbD window.[PDF]
189Hb J-Torontoα1 or α2VARIANT IIDual Kit Program201.693Heterozygote. Clinically normal. [PDF]
193Hb Chicagoα2VARIANT IIDual Kit Program82.31.767Heterozygous. Elutes as HbA. [PDF]
194Hb Chicagoα2VARIANT IIDual Kit Program82.31.767Heterozygous. Elutes as HbA. [PDF]
198Hb HikariβVARIANT IIDual Kit Program31.51.753Clinically normal. [PDF]
202Hb G-SzuhuβVARIANT IIDual Kit Program3.23.017[PDF]
206Hb Ambroise Pareα2VARIANT IIDual Kit Program80.71.797Heterozygous. Elutes with HbA. [PDF]
210Hb Groene Hartα1VARIANT IIDual Kit Program801.772Mild non-deletional alpha thal variant. Migrates as HbA. [PDF]
214Hb Q-Thailandα1VARIANT IIDual Kit Program23.83.644heterozygote[PDF]
219Hb Milledgevilleα1 or α2VARIANT IIDual Kit Program84.11.82Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
223Hb Nunobikiα1 or α2VARIANT IIDual Kit Program61.55Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
235Hb RandwickβVARIANT IIDual Kit Program61.22.98Double heterozygote (Hb Randwick with Beta thalassemia). It elutes in the position of HbA0 in all the systems except in the VARIANT II Dual Beta Thal program where it co-elutes with HbA2. Its association with a beta thal is extremely rare and explains both the anaemia and an increased HbF and HbA2 and if it is a beta 0 thal all the fraction eluting at the position of HbA0 is the variant.[PDF]
240HbSβVARIANT IIDual Kit Program86.63.44Sickle cell disease. The trace amount of HbA remains from a blood transfusion.[PDF]
244HbSβVARIANT IIDual Kit Program68.93[PDF]
245HbSβVARIANT IIDual Kit Program68.93[PDF]
246HbSβVARIANT IIDual Kit Program68.93.45[PDF]
250HbSβVARIANT IIDual Kit Program24.13.49HbS carrier with homozygous alpha + thalassemia.[PDF]
253HbSβVARIANT IIDual Kit Program77.93.48Homozygous HbS with high HbA1c.[PDF]
257Hb G-Philadelphiaα1 or α2VARIANT IIDual Kit Program28.93.35Heterozygous. Eluates as HbS. Associated with alpha thal. [PDF]
261HbCβVARIANT IIDual Kit Program24.94.438Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. [PDF]
264HbSβVARIANT IIDual Kit Program73.73.387Classical chromatogram of a SS patient, the high HbF level suggests that the patient may be heterozygote (or perhaps homozygote) for one of the haplotype stimulating HbF synthesis.[PDF]
268HbCβVARIANT IIDual Kit Program32.24.433heterozygote[PDF]
272Hb D-IranβVARIANT IIDual Kit Program392.71Heterozygous. Elutes as HbA2 in CE-HPLC. [PDF]
276Hb Hasharonα1VARIANT IIDual Kit Program19.24.19heterozygote[PDF]
280Hb Hopkins-IIα1 or α2VARIANT IIDual Kit Program19.51.5heterozygote[PDF]
284Hb J-BangkokβVARIANT IIDual Kit Program32.31.66heterozygote[PDF]
288Hb J-Broussaisα1 or α2VARIANT IIDual Kit Program12.21.48Heterozygote. Elutes near or with HbA1c. [PDF]
292Hb J-Paris-Iα1VARIANT IIDual Kit Program25.51.59heterozygote
296Hb J-Paris-Iα2VARIANT IIDual Kit Program350.55Heterozygote. Elutes together with HbF. [PDF]
300Hb Le Lamentinα2VARIANT IIDual Kit Program25.51.41heterozygote[PDF]
304Hb O-ArabβVARIANT IIDual Kit Program30.64.01Heterozygote, clinically normal. [PDF]
308Hb O-Padovaα1 or α2VARIANT IIDual Kit Program14.53.93Heterozygote. Clinically normal.[PDF]
312Hb Q-Indiaα1VARIANT IIDual Kit Program14.93.93Heterozygote. Clinically normal.[PDF]
316HbSβVARIANT IIDual Kit Program33.33.47HbS homozygote, transfused. [PDF]
320Hb D-IbadanβVARIANT IIDual Kit Program35.83.17Carrier. Clinically normal. [PDF]
324Hb VallettaβVARIANT IIDual Kit Program81.61.75Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.[PDF]
330Hb St. Luke'sα1VARIANT IIDual Kit Program8.83.68Heterozygous.[PDF]
334Hb Sunshine Sethα2VARIANT IIDual Kit Program15.23.956heterozygote[PDF]
338HbEβVARIANT IIDual Kit Program69.42.9Homozygote.[PDF]
342Hb TacomaβVARIANT IIDual Kit Program67.11.77Heterozygote carriers are clinically normal. [PDF]
346Hb Old Dominion/Burton-upon-Trent (OD/BuT)βVARIANT IIDual Kit Program38.91.58heterozygote[PDF]
350Hb Hopkins-IIα1 or α2VARIANT IIDual Kit Program22.61.49Heterozygote.[PDF]
354Hb G-Philadelphiaα1 or α2VARIANT IIDual Kit Program233.37Heterozygous. Elutes as HbS. Associated with alpha thal. [PDF]
356Hb J-BangkokβVARIANT IIDual Kit Program26.41.7Clinically normal. Rare but found worldwide. [PDF]
360Hb Q-Iranα1 or α2VARIANT IIDual Kit Program19.24.09heterozygote[PDF]
364HbCβVARIANT IIDual Kit Program74.84.41Homozygous.[PDF]
368Hb Le Lamentinα2VARIANT IIDual Kit Program29.11.47heterozygote[PDF]
372Hb J-Meerutα2VARIANT IIDual Kit Program9.51.53heterozygote[PDF]
375Hb Winnipegα1VARIANT IIDual Kit Program16.14.084Heterozygote.[PDF]
379Hb Seal Rockα2VARIANT IIDual Kit Program0.74.104Heterozygous. Modified C-terminal sequence.[PDF]
383Hb D-PunjabβVARIANT IIDual Kit Program38.53.233heterozygote[PDF]
387Hb G-AccraβVARIANT IIDual Kit Program43.13.144Normal in the heterozygote.[PDF]
391Hb HopeβVARIANT IIDual Kit Program47.80.921In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote. [PDF]
395Hb AustinβVARIANT IIDual Kit Program441.592Normal in the heterozygote. [PDF]
399HbSβVARIANT IIDual Kit Program27.13.487HbS carrier with alpha thalassemia (homoz. alpha 3.7). [PDF]
403HbSβVARIANT IIDual Kit Program30.53.499HbS + alpha-thal 2 (-3.7 del.).[PDF]
408Hb G-CopenhagenβVARIANT IIDual Kit Program38.82.896Clinically normal. Elutes together with HbA2. [PDF]
412Hb G-San JoséβVARIANT IIDual Kit Program32.93.564Clinically normal. [PDF]
416HbCβVARIANT IIDual Kit Program78.94.416Homozygote.[PDF]
420Hb Santa ClaraβVARIANT IIDual Kit Program45.61.522Heterozygote.[PDF]
424Hb D-PunjabβVARIANT IIDual Kit Program30.63.276Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.[PDF]
428Hb Hasharonα1VARIANT IIDual Kit Program25.94.205Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
432Hb Hasharonα1VARIANT IIDual Kit Program274.207Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
436HbEβVARIANT IIDual Kit Program25.92.926heterozygote[PDF]
440Hb AbruzzoβVARIANT IIDual Kit Program38.82.836Hb with increased oxygen affinity. [PDF]
444Hb G-San JoséβVARIANT IIDual Kit Program31.33.623Clinically normal. [PDF]
448Hb RomaβVARIANT IIDual Kit Program31.33.623Elutes with HbA. [PDF]
451Hb CamperdownβVARIANT IIDual Kit Program45.50.958Hb variant is mildly unstable. [PDF]
455Hb RandwickβVARIANT IIDual Kit Program2.92.995Elutes with HbA2. Mildly unstable. [PDF]
184Hb Dunnα1 or α2VARIANT IIβ-thal Short Program12.64.01Heterozygote. Elutes in HbD window.[PDF]
188Hb J-Torontoα1 or α2VARIANT IIβ-thal Short Program22.41.88Heterozygote. Clinically normal.[PDF]
192Hb Chicagoα2VARIANT IIβ-thal Short Program852.5Heterozygous. Elutes as HbA. [PDF]
197Hb HikariβVARIANT IIβ-thal Short Program34.52.13Clinically normal. [PDF]
201Hb G-SzuhuβVARIANT IIβ-thal Short Program34.52.13[PDF]
205Hb Ambroise Pareα2VARIANT IIβ-thal Short Program83.32.5Heterozygous. Elutes with HbA. [PDF]
209Hb Groene Hartα1VARIANT IIβ-thal Short Program82.42.5Mild non-deletional alpha thal variant. Migrates as HbA. [PDF]
213Hb Q-Thailandα1VARIANT IIβ-thal Short Program86.94.38heterozygote[PDF]
218Hb Milledgevilleα1 or α2VARIANT IIβ-thal Short Program22.32.26Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
222Hb Nunobikiα1 or α2VARIANT IIβ-thal Short Program12.71.6Heterozygous. Increased oxygen affinity leading to a mild erythrocytosis.[PDF]
239HbSβVARIANT IIβ-thal Short Program91.14.45Sickle cell disease. The trace amount of HbA remains from a blood transfusion.[PDF]
243HbSβVARIANT IIβ-thal Short Program75.34.43Homozygous HbS recently transfused. [PDF]
249HbSβVARIANT IIβ-thal Short Program25.34.43HbS carrier with homozygous alpha + thalassemia.[PDF]
252HbSβVARIANT IIβ-thal Short Program79.84.47Homozygous HbS. HbA remains from a blood transfusion. [PDF]
256Hb G-Philadelphiaα1 or α2VARIANT IIβ-thal Short Program294.12Heterozygous. Eluates as HbD. Associated with alpha thal. [PDF]
260HbCβVARIANT IIβ-thal Short Program25.15.11Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. [PDF]
267HbCβVARIANT IIβ-thal Short Program33.95.17heterozygote[PDF]
271Hb D-IranβVARIANT IIβ-thal Short Program38.73.54Heterozygous. Elutes as HbA2 in CE-HPLC. [PDF]
275Hb Hasharonα1VARIANT IIβ-thal Short Program204.82heterozygote[PDF]
279Hb Hopkins-IIα1 or α2VARIANT IIβ-thal Short Program191.51heterozygote[PDF]
283Hb J-BangkokβVARIANT IIβ-thal Short Program38.71.92heterozygote[PDF]
287Hb J-Broussaisα1 or α2VARIANT IIβ-thal Short Program28.11.65Heterozygote. Elutes near or with HbA1c.[PDF]
291Hb J-Paris-Iα1VARIANT IIβ-thal Short Program26.21.71heterozygote[PDF]
295Hb J-Sardegnaα2VARIANT IIβ-thal Short Program34.31.19Heterozygote. Elutes together with HbF. [PDF]
299Hb Le Lamentinα2VARIANT IIβ-thal Short Program25.61.49heterozygote[PDF]
303Hb O-ArabβVARIANT IIβ-thal Short Program32.34.91Heterozygote, clinically normal. [PDF]
307Hb O-Padovaα1 or α2VARIANT IIβ-thal Short Program16.74.79Heterozygote. Clinically normal.[PDF]
311Hb Q-Indiaα1VARIANT IIβ-thal Short Program17.24.79Heterozygote. Clinically normal.[PDF]
315HbSβVARIANT IIβ-thal Short Program36.94.43HbS homozygote, transfused. [PDF]
319Hb D-IbadanβVARIANT IIβ-thal Short Program39.13.94Carrier. Clinically normal. [PDF]
323Hb VallettaβVARIANT IIβ-thal Short Program85.82.39Heterozygous. Elutes with HbA. Clinically normal. This mutation is usually linked in cis to HbF Malta.[PDF]
325Hb F-Malta-IVARIANT IIβ-thal Short Program49.71.16Heterozygous. Elutes near to HbF. Clinically normal. Associated in cis to Hb Valletta.[PDF]
326Hb F-Malta-IVARIANT IIβ-thal Short Program53.31.17Heterozygous. Elutes near to HbF. Clinically normal. Associated in cis to Hb Valletta.[PDF]
328Hb St. Luke'sα1VARIANT IIβ-thal Short Program9.44.46Heterozygous. Elutes with HbS. [PDF]
329Hb St. Luke'sα1VARIANT IIβ-thal Short Program8.84.58Heterozygous. Elutes with HbS. [PDF]
333Hb Sunshine Sethα2VARIANT IIβ-thal Short Program164.79heterozygote[PDF]
337HbEβVARIANT IIβ-thal Short Program69.53.64Homozygote.[PDF]
341Hb TacomaβVARIANT IIβ-thal Short Program71.42.41Heterozygote carriers are clinically normal.[PDF]
345Hb Old Dominion/Burton-upon-Trent (OD/BuT)βVARIANT IIβ-thal Short Program33.21.88heterozygote[PDF]
349Hb Hopkins-IIα1 or α2VARIANT IIβ-thal Short Program10.31.6Heterozygote.[PDF]
353Hb G-Philadelphiaα1 or α2VARIANT IIβ-thal Short Program21.54.13Heterozygous. Elutes as HbD. Associated with alpha thal. [PDF]
355Hb J-BangkokβVARIANT IIβ-thal Short Program34.52.02Clinically normal. Rare but found worldwide. [PDF]
359Hb Q-Iranα1 or α2VARIANT IIβ-thal Short Program21.24.85heterozygote[PDF]
363HbCβVARIANT IIβ-thal Short Program18.54.86[PDF]
367Hb Le Lamentinα2VARIANT IIβ-thal Short Program5.61.66heterozygote[PDF]
371Hb J-Meerutα2VARIANT IIβ-thal Short Program7.41.65heterozygote[PDF]
378Hb Seal Rockα2VARIANT IIβ-thal Short Program0.94.77Heterozygous. Modified C-terminal sequence.[PDF]
382Hb D-PunjabβVARIANT IIβ-thal Short Program37.34.14heterozygote[PDF]
386Hb G-AccraβVARIANT IIβ-thal Short Program43.53.89Normal in the heterozygote. [PDF]
390Hb HopeβVARIANT IIβ-thal Short Program47.81.4In neonatal screening this Hb may be masked by the large amount of HbF and a baby compound heterozygous for HbS and Hb Hope may erroneously appear as an HbS homozygote. [PDF]
394Hb AustinβVARIANT IIβ-thal Short Program45.81.75Normal in the heterozygote. [PDF]
398HbSβVARIANT IIβ-thal Short Program27.54.43HbS carrier with alpha thalassemia (homoz. alpha 3.7). [PDF]
402HbSβVARIANT IIβ-thal Short Program31.94.44HbS carrier + alpha-thal 2 (-3.7 del.). [PDF]
407Hb G-CopenhagenβVARIANT IIβ-thal Short Program39.23.75Clinically normal. Elutes together with HbA2. [PDF]
411Hb G-San JoséβVARIANT IIβ-thal Short Program36.64.6Clinically normal. Elutes in S Window. [PDF]
415HbCβVARIANT IIβ-thal Short Program85.45.13Homozygote.[PDF]
419Hb Santa ClaraβVARIANT IIβ-thal Short Program45.91.66Heterozygote.[PDF]
423Hb D-PunjabβVARIANT IIβ-thal Short Program28.84.08Heterozygous. Clinically normal in heterozygotes. Mild anemia in homozygotes.[PDF]
427Hb Hasharonα1VARIANT IIβ-thal Short Program27.14.82Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
435HbEβVARIANT IIβ-thal Short Program25.13.65heterozygote[PDF]
439Hb AbruzzoβVARIANT IIβ-thal Short Program423.39Hb with increased oxygen affinity. [PDF]
443Hb G-San JoséβVARIANT IIβ-thal Short Program33.34.6Clinically normal. Elutes in S Window. [PDF]
447Hb RomaβVARIANT IIβ-thal Short Program3.334.6Elutes with HbA. [PDF]
450Hb CamperdownβVARIANT IIβ-thal Short Program43.11.34Hb variant is mildly unstable. [PDF]
454Hb RandwickβVARIANT IIβ-thal Short Program81.82.41Elutes with HbA. Mildly unstable. [PDF]
456HbSβVARIANT IIDual Kit Program - HbA1c44.92.035Compound heterozygote between HbS and HbC[PDF]
461HbEβVARIANT IIDual Kit Program18.92.91HbE heterozygote with alpha-thal 1 heterozygote.[PDF]
465HbEβVARIANT IIDual Kit Program27.22.899Association of HbE and Hb Constant Spring[PDF]
469HbSβVARIANT IIDual Kit Program68.53.437Heterozygote for Hb S/beta zero thal (Beta(0) CD39 (C/T)). [PDF]
472Hb ShelbyβVARIANT IIDual Kit Program12.22.968Compound heterozygous Hb Shelby / Beta zero Thalassemia. [PDF]
476Hb ShelbyβVARIANT IIDual Kit Program3.92.979heterozygote[PDF]
480Hb D-PunjabβVARIANT IIDual Kit Program75.43.191Double heterozygote Hb D-Punjab and beta-thalassaemia. [PDF]
485Hb VallettaβVARIANT IIDual Kit Program61.21.886Compound heterozygote with Hb Lepore. Elutes as HbA0. [PDF]
487Hb D-PunjabβVARIANT IIDual Kit Program84.83.212[PDF]
498HbSβVARIANT IIDual Kit Program38.63.472Hb S/beta thal (probably a delta-beta thalassemia). [PDF]
502HbSβVARIANT IIDual Kit Program6.93.545Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.[PDF]
506HbSβVARIANT IIDual Kit Program53.63.465HbS homozygous with HPFH.[PDF]
512HbSβVARIANT IIDual Kit Program45.73.427Compound heterozygote for HbS and HbC[PDF]
513HbCβVARIANT IIDual Kit Program42.74.422Compound heterozygote for HbC and HbS[PDF]
516HbSβVARIANT IIDual Kit Program70.63.402Compound heterozygote for HbS and Beta (+) thal.[PDF]
521HbSβVARIANT IIDual Kit Program46.73.429Compound heterozygote for HbS and HbC[PDF]
522HbCβVARIANT IIDual Kit Program43.24.431Compound heterozygote for HbS and HbC.[PDF]
526HbSβVARIANT IIDual Kit Program59.53.432Compound heterozygote for HbS and B (+) thalassaemia.[PDF]
533HbSβVARIANT IIDual Kit Program44.63.44Compound heterozygote for HbS and HbC.[PDF]
534HbCβVARIANT IIDual Kit Program40.84.423Compound heterozygote for HbS and HbC[PDF]
540Hb D-PunjabβVARIANT IIDual Kit Program403.21Compound heterozygote for HbS and Hb D-Punjab[PDF]
541HbSβVARIANT IIDual Kit Program37.53.455Compound heterozygote for HbS and Hb D-Punjab.[PDF]
545HbCβVARIANT IIDual Kit Program504.414Compound heterozygote for HbC and (delta-beta) zero thalassaemia. [PDF]
549HbCβVARIANT IIDual Kit Program59.34.422Compound heterozygote for HbC and beta-thalassaemia. [PDF]
551Hb Goudaα2VARIANT IIDual Kit Program33.31.557heterozygote[PDF]
555Hb A2' or Hb B2δVARIANT IIDual Kit Program0.83.62Homozygous.[PDF]
558Hb N-BaltimoreβVARIANT IIDual Kit Program791.535Hb N-Baltimore / Beta zero thalassaemia. Clinical normal. [PDF]
562HbSβVARIANT IIDual Kit Program31.13.452HbS carrier + alpha-thal 2 (-3.7 deletion). [PDF]
567HbEβVARIANT IIDual Kit Program42.62.885Association of HbE and beta-thalassaemia. [PDF]
574HbCβVARIANT IIDual Kit Program43.84.419Compound heterozygosity for HbC and Hb O Arab.[PDF]
575Hb O-ArabβVARIANT IIDual Kit Program42.13.999Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome. [PDF]
580Hb Mexicoα1 or α2VARIANT IIDual Kit Program28.11.49Heterozygous.[PDF]
584HbIα1VARIANT IIDual Kit Program22.51.467heterozygote[PDF]
588Hb Lepore-Boston-WashingtonδVARIANT IIDual Kit Program13.12.827Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
588Hb Lepore-Boston-WashingtonβVARIANT IIDual Kit Program13.12.827Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
592Hb M-Milwaukee-2βVARIANT IIDual Kit Program31.14.435Congenital methemoglobinemia. [PDF]
596Hb Lepore-Boston-WashingtonδVARIANT IIDual Kit Program10.82.887Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
596Hb Lepore-Boston-WashingtonβVARIANT IIDual Kit Program10.82.887Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
598HbIα1VARIANT IIDual Kit Program27.91.491Heterozygote.[PDF]
602Hb Aichiα1 or α2VARIANT IIDual Kit Program22.53.465Heterozygous. Elutes as HbS. [PDF]
605Hb Setifα2VARIANT IIDual Kit Program61.529Heterozygote. Elutes with HbA. [PDF]
611Hb Setifα2VARIANT IIDual Kit Program10.43.908Heterozygote. [PDF]
614HbSβVARIANT IIDual Kit Program28.83.489HbS carrier with Hb Montgomery (alpha variant). [PDF]
615Hb Montgomeryα2VARIANT IIDual Kit Program6.54.425Heterozygous. Association with HbS. [PDF]
460HbEβVARIANT IIβ-thal Short Program19.43.68HbE heterozygote with alpha-thal 1 heterozygote.[PDF]
464HbEβVARIANT IIβ-thal Short Program27.13.68Association of HbE and Hb Constant Spring[PDF]
468HbSβVARIANT IIβ-thal Short Program77.54.43Heterozygote for Hb S/beta zero thal (Beta(0) CD39 (C/T)).[PDF]
475Hb ShelbyβVARIANT IIβ-thal Short Program4.43.66heterozygote[PDF]
479Hb D-PunjabβVARIANT IIβ-thal Short Program77.84.08Double heterozygote Hb D-Punjab and beta-thalassaemia. [PDF]
481Hb SiirtβVARIANT IIβ-thal Short Program82.92.54Elutes together with HbA. [PDF]
484Hb VallettaβVARIANT IIβ-thal Short Program66.12.65Compound heterozygote with Hb Lepore. Elutes as HbA0. [PDF]
495Hb RandwickβVARIANT IIβ-thal Short Program66.82.66Double heterozygote for Hb Randwick and beta-thalassaemia. [PDF]
497HbSβVARIANT IIβ-thal Short Program53.54.46Hb S/beta thal (probably a delta-beta thalassemia). [PDF]
501HbSβVARIANT IIβ-thal Short Program11.84.36Newborn homozygous for HbS. The peak eluting at the position of HbA2 may be aged HbS.[PDF]
505HbSβVARIANT IIβ-thal Short Program64.14.45HbS homozygous with HPFH.[PDF]
525HbSβVARIANT IIβ-thal Short Program664.44Compound heterozygote for HbS and B (+) thalassemia[PDF]
531HbSβVARIANT IIβ-thal Short Program45.94.45Compound heterozygote for HbS and HbC[PDF]
532HbCβVARIANT IIβ-thal Short Program44.65.17Compound heterozygote for HbS and HbC[PDF]
538Hb D-PunjabβVARIANT IIβ-thal Short Program414.06Compound heterozygote for HbS and Hb D-Punjab.[PDF]
539HbSβVARIANT IIβ-thal Short Program374.42Compound heterozygote for HbS and Hb D-Punjab.[PDF]
544HbCβVARIANT IIβ-thal Short Program60.55.15Compound heterozygote for HbC and (delta-beta) zero thalassaemia. [PDF]
548HbCβVARIANT IIβ-thal Short Program61.85.16Compound heterozygote for HbC and beta-thalassaemia. [PDF]
550Hb Goudaα2VARIANT IIβ-thal Short Program31.11.7heterozygote[PDF]
554Hb A2' or Hb B2δVARIANT IIβ-thal Short Program4.550.9Homozygous.[PDF]
557Hb N-BaltimoreβVARIANT IIβ-thal Short Program81.31.61Hb N-Baltimore / Beta zero thalassaemia. Clinical normal. [PDF]
561HbSβVARIANT IIβ-thal Short Program32.54.46HbS carrier + alpha-thal 2 (-3.7 deletion). [PDF]
566HbEβVARIANT IIβ-thal Short Program51.63.69Association of HbE and beta-thalassaemia. [PDF]
572HbCβVARIANT IIβ-thal Short Program47.75.15Compound heterozygote for HbC and Hb O-Arab.[PDF]
573Hb O-ArabβVARIANT IIβ-thal Short Program46.14.9Compound heterozygosity for HbC and Hb O Arab (extremely rare). This situation is important to be identified for genetic counselling since both alleles when associated to HbS lead to a severe sickle cell syndrome. [PDF]
578Hb Mexicoα1 or α2VARIANT IIβ-thal Short Program27.71.82Heterozygous.[PDF]
583HbIα1VARIANT IIβ-thal Short Program14.91.4heterozygote[PDF]
587Hb Lepore-Boston-WashingtonδVARIANT IIβ-thal Short Program11.13.55Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
587Hb Lepore-Boston-WashingtonβVARIANT IIβ-thal Short Program11.13.55Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
591Hb M-Milwaukee-2βVARIANT IIβ-thal Short Program34.15.15Congenital methemoglobinemia. [PDF]
595Hb Lepore-Boston-WashingtonδVARIANT IIβ-thal Short Program10.83.5Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
595Hb Lepore-Boston-WashingtonβVARIANT IIβ-thal Short Program10.83.5Mild microcytic anaemia. Elutes together with HbA2 in CE-HPLC. [PDF]
597HbIα1VARIANT IIβ-thal Short Program18.11.43Heterozygote. [PDF]
601Hb Aichiα1 or α2VARIANT IIβ-thal Short Program21.14.33Heterozygous. Elutes as HbS. [PDF]
610Hb Setifα2VARIANT IIβ-thal Short Program13.24.74Heterozygote. [PDF]
612HbSβVARIANT IIβ-thal Short Program37.94.46HbS carrier with Hb Montgomery (alpha variant). [PDF]
613Hb Montgomeryα2VARIANT IIβ-thal Short Program6.34.98Heterozygous. Association with HbS. [PDF]
457HbSβVARIANT IIDual Kit Program - HbA1c85.61.87Classic chromatogram of an SS patient. [PDF]
466HbSβVARIANT IIHbA1c Program52.11.94Compound heterozygote between HbS and HbC[PDF]

Please Contact Us to provide new HPLC data and/or report mistakes.

Disclaimer: The HPLC images are provided by Bio-Rad Laboratories, Inc as an information resource only. Bio-Rad Laboratories, Inc and the ITHANET Portal disclaim responsibility and have no liability if this information is used for diagnostic or treatment purposes. D-10™ and VARIANT™ are registered trademarks of Bio-Rad Laboratories, Inc. and used with permission. Redistribution and use of the above material is allowed only with permission by Bio-Rad Laboratories, Inc.

Future events

  • Pan-European Consensus Conference on Newborn Screening for Haemoglobinopathies
  • ASGCT 2017 Annual Meeting
  • 7th IVI International Congress
  • 2nd Congress of Gene Therapy and Regenerative Medicine
  • European Human Genetics Conference 2017

View all events

Find Us